INTRODUCTION
Previous work from our laboratory has indicated that induction of hemoglobin synthesis and terminal erythroid maturation in MEL cell is associated with changes in methylation of both polyA + and polyA -RNA as well as with alterations in the intracellular concentration of SAH/SAM ratio involved in the active methylation cycle (1, 2) . Such a conclusion was further supported by the observation that N 6 -methyladenosine (N 6 mAdo) inhibits commitment of MEL cells to terminal maturation induced by chemical inducers through its intracellular conversion into S-N 6 -methyladenosylhomocysteine (N 6 -SAH), an active intermediate that affects methylation of RNA. The potential role of changes in RNA methylation was further strengthened by data showing that pharmacological agents which inhibit active methylation cycle block MEL cell differentiation program in vitro and trigger the cytoplasmic accumulation of relatively short RNA transcripts lacking polyA-tail (1) (2) (3) (4) . Molecular hybridization mapping analysis has revealed that these RNAs are likely to be encoded by DNA sequences located downstream from 3΄-end of β major globin gene. To understand the role of these RNA transcripts in the blockade of MEL erythroid maturation, it was critical to clone and characterize these RNA species and identify their sequences and origin. In this study, we have structurally characterized the 3΄-end flanking β major globin DNA sequences that presumably encode polyA -RNA transcripts accumulated upon blockade of MEL cell differentiation with methylation inhibitors by cloning and characterizing these molecules. To this end, we have carried out two sets of studies. In the first, we made an effort to map DNA sequences located downstream from the 3΄-end of β major globin gene that presumably encode the polyA -RNAs and in the second, to clone and further characterize the relatively low molecular weight RNA transcripts. These studies revealed a DNA region of 559 bp (designated B1-559) that contains several ATG initiation codons, a B1-retrotransposon element and shares structural homology with at least two RNA species (151 and 448 nt) out of four RNA transcripts cloned (151, 174, 391 and 448 nt) upon treatment of MEL cells with methylation inhibitors. Recently, we have demonstrated the capacity of B1-559 to recruit binding of nuclear trans-acting proteins derived from MEL cells as well as to activate transient expression of a reporter gene in hematopoietic cells either alone or in cooperation with DNase I hypersensitive site 2 (HS2) sequences of β-globin gene LCR enhancer (5) . The implication of methylation inhibitors-induced activation of B1-like silent DNA regions in patients undergoing cancer chemotherapy using hypomethylating agents as antineoplastic agents are discussed. http://bmbreports.org BMB reports To analyze both structurally and functionally the 3΄-end downstream flanking β major globin sequences and demonstrate or rule out the possibility whether the polyA -RNA transcripts originate from this DNA region, an experimental strategic approach was applied that aimed to: a) map the region of possible origin of RNA species; b) uncover the protected RNA species by S1 nuclease mapping and confirm their origin of transcription; and c) clone and identify RNA transcripts via RT-PCR and subsequent sequencing of cloned cDNAs. At first, four DNA probes were generated (Fr1, Fr2, Fr3 and Fr4) by PCR covering the 3΄-flanking β major globin gene region being under analysis (Fig. 1A) for subsequent use in Northern blot hybridization analysis experiments to locate the origin of RNA molecules. Interestingly enough, the molecular hybridization revealed that only DNA probes Fr1 (Fig. 1B), Fr2 (Fig.  1C) and Fr3 (Fig. 1D ) but not Fr4 (Fig. 1E) allowed the detection of short-ended RNA transcripts. Such a finding suggested that the origin of RNA species might be located adjacent to the B1 element previously found at the 3΄-flanking β major globin gene DNA sequences (see Fig. 1A ) (4) . Subsequently, nuclease-S1 mapping was carried out to assess RNA molecules being protected by the 7.304 bp genomic DNA fragment when cytoplasmic RNA derived from MEL cells exposed to methylation inhibitors was hybridized. Following this direction, the presence of β major globin mRNA and another lower molecular weight RNA was confirmed (Fig. 2B) . The β major globin mRNA was protected from nuclease-S1 degradation, although it was detected at lower molecular weight as compared to the original intact molecule. This result should be interpreted by the existence of polyA-tail added post-transcriptionally in the intact β major globin mRNA.
Cloning and characterization of RNA transcripts accumulated in the cytoplasm of MEL cells exposed to methylation inhibitors
As we have shown previously, exposure of MEL cells to neplanocin A, 3-deazaneplanocin A and cycloleucine specifically blocks erythroid differentiation program and leads to cytoplasmic accumulation of relatively small size polyA-RNA transcripts (1-4). Consequently, the next experimental task was then the identification of such short-ended RNA transcripts via cloning and sequencing. Despite the technical difficulties experienced at the beginning of this study, we were able to clone four RNA molecules by RT-PCR rapid cloning using primers derived from DNA sequences located downstream from the 3΄-flanking β major globin gene region (B1-559) (Fig. 1A) . Indeed, four RNA species were amplified in RT-PCR when cytoplasmic RNA isolated from DMSO-treated MEL cultures in the presence of neplanocin A for 72 hr was used (Fig. 3A) . To confirm the integrity of cytoplasmic RNA and the quality of the synthesized cDNAs, additional PCR was performed by using specific pair of primers able to amplify the developmentally regulated β major globin ( Fig. 3B ) and the housekeeping β-actin (Fig. 3C ) genes. The size of the identified RNA molecules corresponding to the cloned DNA fragments isolated by RT-PCR has been 448, 391, 174 and 151 nt in length (the accession numbers of these clones in Gen/EMBL databank are FM992847, FM992 848, FM992849, FM992850, respectively). Searching in DNA sequence databanks revealed that these RNA molecules share structural homology with DNA sequences located in mouse genome at chromosome 3 for 448 nt (similarity 99%; NT_039240. 7/Mm3_39280_37; position: 44472674-44473110), at chromosome 5 for 391 nt (similarity 98%; NT_078458.6/Mm5_78523_ 37; position: 9624002-9623626), at chromosome 9 for 174 nt (similarity 97%; NW_001030907.1/Mm9_11172196_37; position:34369047-34369207) and at chromosome 3 for 151 nt http://bmbreports.org (partial sequence similarity 83%; NT_039240_7/Mm3_39280_3 7; position: 71554045-71554158) (see supplementary Fig. S1-S4 ). Bioinformatic analysis has shown that the 5΄-end of the 448 nt cloned RNA transcript shares structural homology with the 5΄-end of the B1 element in B1-559 sequence that, as it has been already mentioned, is located downstream from the 3΄-flanking DNA sequences of β major globin gene (Fig. 1A) . In fact, the first 126 nt of these sequences are similar up to ∼93%, as shown in Fig. 3D (see also supplementary Fig. S1 ). Interestingly, the second cloned 151 nt RNA transcript was found to share high degree of similarity at their 5΄-ends of both 448 nt cloned RNA molecule and the B1 element (first 126 bp) ( Fig. 3D and E) (see also supplementary Fig. S4 ). Another interesting point that emerged from these RT-PCR experiments is the fact that, among the cloned RNAs, variability in their steady-state level exists among the different treatment conditions employed in MEL cell cultures. To this regard, it has to be noticed, that mainly the concomitant exposure of MEL cells with DMSO and neplanocin A activated to a greater extent the expression level of such RNAs (Fig. 3A) . In particular, the 448 nt cloned RNA transcript has shown low expression level in parental control-untreated MEL cells, not detectable levels in neplanocin-treated and high level of expression in DMSO-treated that was further enhanced upon co-treatment of cells with DMSO and neplanocin for 72 hr. On the other hand, only the cloned 151 nt RNA transcript exhibited hardly detectable levels in DMSO-treated cells, whereas the other two 391 nt and 174 nt RNAs retained detectable expression levels only upon co-treatment of MEL cells with DMSO and neplanocin.
Expression profile analysis of the cloned 448 nt RNA transcript in control and differentiating MEL cells exposed to methylation inhibitors
Based on the previous data showing that the cloned 448 nt RNA transcript share common DNA sequences with the B1 element in high homology and the fact that the detection of RNA species in the cytoplasm of MEL cells treated with methylation inhibitors was achieved only with probes derived from the vicinity of the B1 element (Fig. 1A) it was reasonable to focus on this RNA molecule and ask if its expression profile in MEL cells exposed to methylation inhibitors is somehow correlated with the steady-state level of RNA transcripts detected by Northern blot hybridization analysis (Fig. 1B, C and D) . To this direction, we used the 448 nt RNA molecule to generate At times indicated (numbers above the panels), total cytoplasmic RNA was isolated from cultures and used (10 μg) to perform Northern blot hybridization analysis using the DNA probes shown in (A) as follows: 448 bp (B), 122 bp (C), or 300 bp (E). In these experiments, the housekeeping gene GAPDH (F) was used as control (4) . In (D, G) the ethidium bromide staining pattern of electrophoresed RNAs is shown. Note that the DNA probes generated from the cloned 448 nt RNA molecule are diagrammatically shown in (A); Sdr: short direct repeats.
inhibitors. As shown diagrammatically in Fig. 4A , the first DNA probe used corresponds to the full length (448 bp) (see data on Fig. 4B) , the second to the initial 122 bp 5΄-end fragment (see data on Fig. 4C ) and the third one contains the rest 300 bp of the molecule (see data on Fig. 4E ). Following this, as illustrated in Fig. 4B, C and E, the use of such DNA probes allowed the detection of more than one RNA species accumulated in the cytoplasm of MEL cells exposed to methylation inhibitors in the presence or absence of DMSO and irrespectively to the probe used. Interestingly, minimum detection of such RNA transcripts was seen in MEL cultures exposed to inducer DMSO for less than 72 hr (Fig. 4B, C and E) . At least three RNA transcripts were detected in the cytoplasm after 48 hr exposure of MEL cells to methylation inhibitors, whereas their level enhanced after 72 hr. These data suggest that the detected three RNA transcripts share structural similarity with the original cloned 448 nt RNA transcript and thus they could represent members of a class of polyA -RNAs transcripts with core structural domain sequences. Such a possibility has been already shown to exist between B1 and the two cloned RNAs (448 nt and 151 nt; Fig. 3D and E) and also proposed by S1 nuclease experiments (Fig. 2B) .
DISCUSSION
Although human cancers are characterized by widespread changes in their genomic DNA methylation and histone modification patterns, the clinical proof-of-concept and specificity for epigenetic cancer therapies remains to be clearly established (6) . Furthermore, it has long been known that in cancer cells repetitive DNA elements suffer abnormal demethylation with potential loss of their silencing status. Interestingly, it has been shown that the activity of L1s during brain development and their contribution to neuronal function by modulating gene expression is mediated through the pivotal role of methyl-CpG-binding protein 2 (MeCP2) by acting as a modulator of L1s neuronal transcription and retrotransposition (7) . To this regard, the pharmacological activity for demethylating drugs is accompanied by a pleiotropic response involving modulation of expression of a large number of genes also implying a lack in target specificity (8) . This evidence is further supported by the fact that besides the known cancer cell heterogeneity, unique pattern changes in the DNA methylation levels of individual repetitive DNA elements have been recorded in healthy persons as well as among patients suffering from bladder cancer, CML and/or acute promyelocytic leukemia (APL) (9) . Also, by using genome-wide microarray approaches to assess methylation level of DNA repetitive elements in patients with head and neck cancers, it was able researchers to show that significant changes exist with loss of DNA methylation to be most pronounced for certain repeat sequences family members (10) . This means that, upon treatment of cancer patients with demethylating drugs to restore pathological epigenetic changes, the pharmacological effect can vary significantly for each repetitive element also impinging on their function for transcriptional gene activation and/or silencing. Recently, an important paradigm for demethylation-dependent modulation of gene expression involving repetitive elements has been revealed. Indeed, azacytidine and decitabine has altered cMet proto-oncogene expression in colon carcinoma and myeloid leukemia cells through demethylation of an antisense promoter located within a LINE-1 element being part of the second intron of the cMet gene (11) . Similar results were also obtained in bladder tumors, where LINE1 promoter hypomethylation contributed to chromosomal instability and altered the functional cancer cell transcriptome. In this case, hypomethylation of LINE-1 promoter has also activated an alternate transcript of cMet, a result that may be related to bladder cancer predisposition and disease progression (12) . MEL cell differentiation system has been proven a useful model to uncover cellular and molecular events of erythropoiesis involved in leukemic cell maturation in vitro (13) (14) (15) . The promoter-like activity of B1-559 DNA region recently shown (5) and the observed structural similarity of the cloned RNA transcripts with the B1 element located within this locus extend our knowledge on how non-coding RNA molecules derived from genomic repetitive sequences can be generated, un-http://bmbreports.org der conditions where MEL cells are blocked to differentiation by the action of methylation inhibitors. These data are also quite interesting in the light of evidence that methylation inhibitors, like 5-azacytidine (azacitidine), 5-aza-2΄-deoxyazacytidine (decitabine) and pyrimidine-2-one β-ribofuranoside (zebularine), currently in use for the therapy of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), exhibited differential hypomethylating capacity in LINE1 DNA repeat sequences as well as in activating genes relevant to leukemogenesis (16) . At present we have no clue what is the precise function of the cloned small RNAs and if are involved in blocking the commitment of MEL cells to erythroid maturation. Alternatively, one can ask whether these RNAs act at transcriptional or even posttranscriptional level to abrogate MEL cell erythroid differentiation. Whether this region plays any role and how upon transcriptional regulation of β-globin gene locus remains to be elucidated. Alternatively, and based on the capacity of B1-559 to act as a potential promoter in erythroid hematopoietic cells as shown in another study (5), we can postulate that B1-559 unmasked by chromatin remodeling processes can act developmentally upon β-globin gene transcriptional regulation by affecting specific LCR and promoter interactions. To this regard, the cytoplasmic accumulation of the cloned RNA transcripts upon exposure of MEL cells with methylation inhibitors imply that hypomethylation of DNA is at least one mechanism underlying their transcriptional activation. Conversely, the interplay between repetitive elements with transcription factors, DNA methylation and even miRNA function tend to suggest that these elements may contribute to specific transcription-related circuits to modulate gene expression upon development and evolution. If such a molecular circuit exists in our case, where B1-559 sequences and the cloned B1-like RNA transcripts (448 nt and 151 nt) confer somehow their function to other gene regulatory factors, it remains to be documented. In any case, however, the ability of methylation inhibitors to activate previously silent genomic regions, such as B1-like elements, represents an interesting observation of pharmacological and clinical value on light of current cancer chemotherapy with DNA demethylating drugs being in use or under development.
MATERIALS AND METHODS
Cell cultures, assessment of differentiation, isolation of cytoplasmic RNA, Northern blot hybridization analysis and S1-nuclease RNA mapping assay
The growth of MEL-745PC-4A cells, assessment of erythroid differentiation in vitro, isolation of cytoplasmic RNA from cultures and subsequent Northern blot hybridization analysis were carried out as described elsewhere (2, 4) . Furthermore, the S1 nuclease protection assay was carried out as previously described (17) .
RT-PCR for the generation of specific DNA fragments derived from 3΄-flanking β major globin sequences used in Northern blot hybridization analysis
The pBluescript (+7.3 kb) plasmid bearing the 7.304 bp genomic DNA fragment that contains the β major globin gene (accession number X14061 at Gen/EMBL databank) was used as template for the generation of DNA probes consisting of fragments Fr1 (1,841 bp), Fr2 (543 bp), Fr3 (203 bp) and Fr4 (1,256 bp) shown in Fig. 1A by using the following pair of primers: forward primer for both DNA probes Fr1 and Fr2: 5΄-CCGCT CGAGATGCCCAGACTTGGCAAATTAG-3΄, with reverse primer for Fr1, 5΄-CTCATCCATTACATCACTGTC-3΄ and reverse primer for Fr2, 5΄-ggaagatcttATCAGCAATCTTTCAAAGTAC-3΄; For DNA probe Fr3: forward primer: 5'-AAAAGGAGTCTCATG CCAGGCG-3' and reverse primer: 5'-CTGTCAAGATATGAGAC TCCT-3', For DNA probe Fr4: forward primer 5'-CAGCAGTTC CCATATTGAAAG-3' and reverse primer 5'-CTCATCCATTACA TCACTGTC-3'. The low-case letters in primer sequences represent specific restriction enzyme sites added to facilitate subsequent cloning. All the PCR products were purified and verified by DNA sequencing.
RT-PCR cloning of RNA transcripts isolated from MEL cells treated with methylation inhibitors
RT reaction (at 37 o C for 90 min) was carried out to generate cDNAs from 10 μg of total cytoplasmic RNA isolated from either untreated parental MEL or MEL cells incubated with DMSO (210 mM) in the absence or presence of neplanocin A (1×10 -6 M) for 72 hr by using 10 μl (0.5 μg/μl) random hexamer primers, and reverse transcriptase (220 U). These cDNAs were purified (PCR purification kit; Qiagen) and then used as templates in PCR to detect any DNA fragments generated by using the following primers derived from the B1-559 downstream bmajor globin gene DNA region:. Forward primer: 5΄-A AAAGGAGTCTCATGCCAGGCG-3΄; reverse primer: 5΄-CTG TCAAGATATGAGACTCCT-3΄. The PCR products were cloned into pCR2.1 vector, sequenced and the data submitted to Gen/ EMBL databank under accession numbers FM992847, FM99 2848, FM992849 and FM992850. For subsequent Northern blot hybridization experiments, the cloned 448 bp DNA fragment was used as template in PCR to generate two smaller DNA fragments of 122 bp and 300 bp length by using suitable pair of primers as follows: Forward primer: 5΄-GAGGAGCTGTATTGAAT GCCGCAGC-3΄, reverse primer 5΄-AAAAGGAGTCTCATGCCA GGCG-3΄ (300 bp DNA fragment); forward primer: 5΄-AAAAGG AGTCTCATGCCAGGCG-3΄, reverse primer 5΄-CTGTCCTGGAA CTCACTCTGTAGACC-3΄ (122 bp DNA fragment). The generated PCR products were then purified and verified by DNA sequencing.
